Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry.

Shosha E, Al Asmi A, Nasim E, Inshasi J, Abdulla F, Al Malik Y, Althobaiti A, Alzawahmah M, Alnajashi HA, Binfalah M, AlHarbi A, Thubaiti IA, Ahmed SF, Al-Hashel J, Elyas M, Nandhagopal R, Gujjar A, Harbi TA, Towaijri GA, Alsharooqi IA, AlMaawi A, Al Khathaami AM, Alotaibi N, Nahrir S, Al Rasheed AA, Al Qahtani M, Alawi S, Hundallah K, Jumah M, Alroughani R; with the Guthy-Jackson Charitable Foundation International Clinical Consortium.

Mult Scler Relat Disord. 2020 Feb;38:101448. doi: 10.1016/j.msard.2019.101448. Epub 2019 Oct 19.

PMID:
32164911
2.

Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity.

Alroughani R, Inshasi J, Al-Asmi A, Alqallaf A, Al Salti A, Shatila A, Boshra A, Canibano B, Deleu D, Al Sharoqi I, Al Khabouri J.

Postgrad Med. 2020 Feb 28:1-9. doi: 10.1080/00325481.2020.1734394. [Epub ahead of print]

PMID:
32089038
3.

A matched case-control study of risk factors associated with multiple sclerosis in Kuwait.

El-Muzaini H, Akhtar S, Alroughani R.

BMC Neurol. 2020 Feb 21;20(1):64. doi: 10.1186/s12883-020-01635-1.

4.

Family planning is the second most relevant factor for treatment decisions after disease activity - Yes.

Alroughani R.

Mult Scler. 2020 Feb 21:1352458519877689. doi: 10.1177/1352458519877689. [Epub ahead of print] No abstract available.

PMID:
32081078
5.

Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience.

Alroughani R, Qadi N, Inshasi J, Shosha E.

Mult Scler J Exp Transl Clin. 2020 Jan 10;6(1):2055217319850195. doi: 10.1177/2055217319850195. eCollection 2020 Jan-Mar.

6.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrj M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T.

Mult Scler Relat Disord. 2019 Nov 25;38:101868. doi: 10.1016/j.msard.2019.101868. [Epub ahead of print]

PMID:
31877445
7.

The FTO gene polymorphism rs9939609 is associated with obesity and disability in multiple sclerosis patients.

Al-Serri A, Alroughani R, Al-Temaimi RA.

Sci Rep. 2019 Dec 13;9(1):19071. doi: 10.1038/s41598-019-55742-2.

8.

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.

Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610. [Epub ahead of print]

PMID:
31762387
9.

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines.

Yamout B, Sahraian M, Bohlega S, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, Hashem S, Alsharoqi I, Khoury S, Alkhawajah M, Koussa S, Al Khaburi J, Almahdawi A, Alsaadi T, Slassi E, Daodi S, Zakaria M, Alroughani R.

Mult Scler Relat Disord. 2020 Jan;37:101459. doi: 10.1016/j.msard.2019.101459. Epub 2019 Oct 18. Review.

PMID:
31670208
10.

Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.

Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S Jr, Roxburgh RH, Kalincik T, Blizzard L, Lugaresi A, Alroughani R, Sajedi SA, Butzkueven H, Pucci E, Spitaleri D, Granella F, Cristiano E, Yamout B, Hughes S, Gouider R, Sánchez Menoyo JL, Olascoaga J, McGuigan C, Shaw C, Kermode AG, Kasa K, Al-Harbi T, Altintas A, Laureys G, Fragoso Y, Hardy TA, Csepany T, Sirbu CA, Decoo D, Sas A, Alvarez-Cermeño JC, Kotkata K, Millán-Pascual J, Taylor BV.

Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994. [Epub ahead of print]

PMID:
31668127
11.

Leptin rs7799039 polymorphism is associated with multiple sclerosis risk in Kuwait.

Dashti M, Alroughani R, Jacob S, Al-Temaimi R.

Mult Scler Relat Disord. 2019 Nov;36:101409. doi: 10.1016/j.msard.2019.101409. Epub 2019 Sep 24.

PMID:
31563075
12.

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study.

Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, Martinez-Lapiscina EH, Brandt AU, Sánchez-Dalmau B, Vidal-Jordana A, Albrecht P, Koska V, Havla J, Pisa M, Nolan RC, Leocani L, Paul F, Aktas O, Montalban X, Balcer LJ, Villoslada P, Outteryck O, Korn T, Petzold A; IMSVISUAL consortium.

Mult Scler J Exp Transl Clin. 2019 Sep 5;5(3):2055217319871582. doi: 10.1177/2055217319871582. eCollection 2019 Jul-Sep.

13.

Prevalence and Burden of Primary Headache Disorders in Kuwaiti Children and Adolescents: A Community Based Study.

Al-Hashel JY, Ahmed SF, Alroughani R.

Front Neurol. 2019 Jul 30;10:793. doi: 10.3389/fneur.2019.00793. eCollection 2019.

14.

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T.

Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.

PMID:
31397221
15.

Risk of relapses during pregnancy among multiple sclerosis patients.

Alroughani R, Akhtar S, Zeineddine M, El Kouzi Y, El Ayoubi NK, Ahmed SF, Behbehani R, Khoury SJ, Al-Hashel JY, Yamout BI.

Mult Scler Relat Disord. 2019 Sep;34:9-13. doi: 10.1016/j.msard.2019.06.007. Epub 2019 Jun 10.

PMID:
31202959
16.

Economic burden of multiple sclerosis on Kuwait health care system.

Alowayesh MS, Ahmed SF, Al-Hashel J, Alroughani R.

PLoS One. 2019 May 14;14(5):e0216646. doi: 10.1371/journal.pone.0216646. eCollection 2019.

17.

The prevalence of multiple sclerosis continues to increase in Kuwait.

Alroughani R, AlHamdan F, Shuaibi S, Ahmed SF, Behbehani R, Lamdhade S, Al-Hashel J.

Mult Scler Relat Disord. 2019 Jul;32:74-76. doi: 10.1016/j.msard.2019.04.033. Epub 2019 Apr 29.

PMID:
31055174
18.

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion.

Alroughani R, Inshasi JS, Deleu D, Al-Hashel J, Shakra M, Elalamy OR, Shatila AO, Al-Asmi A, Al Sharoqi I, Canibano BG, Boshra A.

Neurol Ther. 2019 Jun;8(1):13-23. doi: 10.1007/s40120-019-0129-0. Epub 2019 Mar 15.

19.

Angiopoietin-like proteins in multiple sclerosis.

Al-Temaimi R, Cherian P, Abu-Farha M, Alroughani R.

J Neuroimmunol. 2019 May 15;330:31-34. doi: 10.1016/j.jneuroim.2019.02.006. Epub 2019 Feb 15.

PMID:
30784773
20.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

21.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
22.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.

PMID:
30623864
23.

Use of traditional medicine for primary headache disorders in Kuwait.

Al-Hashel JY, Ahmed SF, Alshawaf FJ, Alroughani R.

J Headache Pain. 2018 Dec 4;19(1):118. doi: 10.1186/s10194-018-0950-3.

24.

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.

Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J.

Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20.

PMID:
30234431
25.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
26.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.

27.

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Menoyo JLS, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 May;22:166. doi: 10.1016/j.msard.2018.02.025. Epub 2018 Feb 24. No abstract available.

PMID:
29807821
28.

Multiple Sclerosis.

Yamout BI, Alroughani R.

Semin Neurol. 2018 Apr;38(2):212-225. doi: 10.1055/s-0038-1649502. Epub 2018 May 23. Review.

PMID:
29791948
29.

Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).

Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S.

Pediatr Neurol. 2018 Jun;83:19-24. doi: 10.1016/j.pediatrneurol.2018.03.007. Epub 2018 Mar 22.

PMID:
29681490
30.

Pediatric multiple sclerosis: a review.

Alroughani R, Boyko A.

BMC Neurol. 2018 Mar 9;18(1):27. doi: 10.1186/s12883-018-1026-3. Review.

31.

Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis.

Behbehani R, Adnan H, Al-Hassan AA, Al-Salahat A, Alroughani R.

Mult Scler Relat Disord. 2018 Apr;21:56-62. doi: 10.1016/j.msard.2018.02.010. Epub 2018 Feb 11.

PMID:
29459346
32.

Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.

Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J.

Neurology. 2018 Mar 6;90(10):e840-e846. doi: 10.1212/WNL.0000000000005065. Epub 2018 Feb 2.

PMID:
29429970
33.

A longitudinal study of JC virus serostatus stability among multiple sclerosis patients.

Alroughani R, Akhtar S, Ahmed S, Al-Hashel J.

Mult Scler Relat Disord. 2018 Feb;20:132-135. doi: 10.1016/j.msard.2018.01.016. Epub 2018 Jan 31.

PMID:
29414286
34.

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22.

PMID:
29182993
35.

Age-Period-Cohort Modeling of Multiple Sclerosis Incidence Rates in Kuwait: 1980-2014.

Akhtar S, Al-Abkal J, Al-Hashel JY, Alroughani R.

Neuroepidemiology. 2017;49(3-4):152-159. doi: 10.1159/000484318. Epub 2017 Nov 21.

PMID:
29161697
36.

Alternative diagnoses in patients referred to specialized centers for suspected MS.

Yamout BI, Khoury SJ, Ayyoubi N, Doumiati H, Fakhreddine M, Ahmed SF, Tamim H, Al-Hashel JY, Behbehani R, Alroughani R.

Mult Scler Relat Disord. 2017 Nov;18:85-89. doi: 10.1016/j.msard.2017.09.016. Epub 2017 Sep 21.

PMID:
29141828
37.

Remyelination modulators in multiple sclerosis patients.

Al-Temaimi R, AbuBaker J, Al-Khairi I, Alroughani R.

Exp Mol Pathol. 2017 Dec;103(3):237-241. doi: 10.1016/j.yexmp.2017.11.004. Epub 2017 Nov 8.

PMID:
29108879
38.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
39.

Burden of migraine in a Kuwaiti population: a door-to-door survey.

Al-Hashel JY, Ahmed SF, Alroughani R.

J Headache Pain. 2017 Oct 13;18(1):105. doi: 10.1186/s10194-017-0814-2.

40.

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.

Achiron A, Aref H, Inshasi J, Harb M, Alroughani R, Bijarnia M, Cooke K, Yuksel O.

BMC Neurol. 2017 Aug 7;17(1):150. doi: 10.1186/s12883-017-0913-3.

41.

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.

Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.

Neurol Ther. 2017 Dec;6(2):189-196. doi: 10.1007/s40120-017-0080-x. Epub 2017 Aug 5.

42.

Prevalence of Primary Headache Disorders in Kuwait.

Al-Hashel JY, Ahmed SF, Alroughani R.

Neuroepidemiology. 2017;48(3-4):138-146. doi: 10.1159/000478892. Epub 2017 Jul 21.

PMID:
28728154
43.

PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients.

Qureshi M, Hatem M, Alroughani R, Jacob SP, Al-Temaimi RA.

Neuromolecular Med. 2017 Sep;19(2-3):286-292. doi: 10.1007/s12017-017-8443-0. Epub 2017 May 23.

PMID:
28536997
44.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
45.

The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.

Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.

Pediatr Neurol. 2017 May;70:56-60. doi: 10.1016/j.pediatrneurol.2017.01.017. Epub 2017 Feb 2.

PMID:
28389054
46.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
47.

Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.

Jacob S, Al-Kandari A, Alroughani R, Al-Temaimi R.

J Neuroimmunol. 2017 Apr 15;305:5-8. doi: 10.1016/j.jneuroim.2017.01.008. Epub 2017 Jan 13.

PMID:
28284345
48.

Sensitivity of visual evoked potentials and spectral domain optical coherence tomography in early relapsing remitting multiple sclerosis.

Behbehani R, Ahmed S, Al-Hashel J, Rousseff RT, Alroughani R.

Mult Scler Relat Disord. 2017 Feb;12:15-19. doi: 10.1016/j.msard.2016.12.005. Epub 2016 Dec 23.

PMID:
28283099
49.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
50.

Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.

Behbehani R, Abu Al-Hassan A, Al-Salahat A, Sriraman D, Oakley JD, Alroughani R.

PLoS One. 2017 Feb 13;12(2):e0172120. doi: 10.1371/journal.pone.0172120. eCollection 2017.

Supplemental Content

Loading ...
Support Center